The Medical Letter on Drugs and Therapeutics
Vilazodone (Viibryd) - A New Antidepressant
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Vilazodone (Viibryd – Forest), a selective serotonin reuptake inhibitor (SSRI) and partial 5-HT1A receptor agonist, has been approved by the FDA for treatment of depression. It has been claimed to have no sexual side effects and not to cause weight gain.

RATIONALE — The manufacturer’s premise is that addition of an agonist at 5-HT1A could possibly lead to an earlier antidepressant effect and a decrease in SSRI-induced sexual side effects.1 Buspirone (Buspar, and others), a 5-HT1A agonist used for treatment of anxiety, has been tried as an add-on to an SSRI in patients not responding adequately to SSRI monotherapy.2

PHARMACOLOGY — Vilazodone peak serum concentrations are higher and the area under the concentration- time curve (AUC) is greater (64-85%) when the drug is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vilazodone (Viibryd) - A New Antidepressant
Article code: 1368a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian